Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial

Azzouzi Abdel-Rahmène; A Azzouzi; Sébastien Vincendeau; Eric Barret; Antony Cicco; Francois Kleinclauss; Henk van der Poel; Christian Stief; Jens Rassweiler; Georg Salomon; Eduardo Solsona; Antonio Alcaraz; Teuvo Tammela; Derek Rosario; Francisco Gomez-Veiga; Göran Ahlgren; Benzaghou Fawzi; Gaillac Bertrand; Billy Amzal; Frans Debruyne; Gaëlle Fromont; Christian Gratzke; Mark Emberton

doi:10.1016/s1470-2045(16)30661-1

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial

Azzouzi Abdel-Rahmène
, A Azzouzi
, Sébastien Vincendeau
, Eric Barret
, Antony Cicco
, Francois Kleinclauss
, Henk van der Poel
, Christian Stief
, Jens Rassweiler
, Georg Salomon
, Eduardo Solsona
, Antonio Alcaraz
, Teuvo Tammela
, Derek Rosario
, Francisco Gomez-Veiga
, Göran Ahlgren
, Benzaghou Fawzi
, Gaillac Bertrand
, Billy Amzal
, Frans Debruyne

Gaëlle Fromont, Christian Gratzke, Mark Emberton

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

310 Sitaatiot (Scopus)

Alkuperäiskieli	Englanti
Sivut	181-191
Julkaisu	The Lancet Oncology
Vuosikerta	18
Numero	2
Varhainen verkossa julkaisun päivämäärä	2016
DOI - pysyväislinkit	https://doi.org/10.1016/s1470-2045(16)30661-1
Tila	Julkaistu - 2017
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

SDG 3 – Hyvä terveys ja hyvinvointi

Julkaisufoorumi-taso

Jufo-taso 2

Pääsy asiakirjaan

10.1016/s1470-2045(16)30661-1

Siteeraa tätä

Abdel-Rahmène, A., Azzouzi, A., Vincendeau, S., Barret, E., Cicco, A., Kleinclauss, F., van der Poel, H., Stief, C., Rassweiler, J., Salomon, G., Solsona, E., Alcaraz, A., Tammela, T., Rosario, D., Gomez-Veiga, F., Ahlgren, G., Fawzi, B., Bertrand, G., Amzal, B., ... Emberton, M. (2017). Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial. The Lancet Oncology, 18(2), 181-191. https://doi.org/10.1016/s1470-2045(16)30661-1

@article{4a0a1a481fc84257b00f256787132529,

title = "Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial",

author = "Azzouzi Abdel-Rahm{\`e}ne and A Azzouzi and S{\'e}bastien Vincendeau and Eric Barret and Antony Cicco and Francois Kleinclauss and \{van der Poel\}, Henk and Christian Stief and Jens Rassweiler and Georg Salomon and Eduardo Solsona and Antonio Alcaraz and Teuvo Tammela and Derek Rosario and Francisco Gomez-Veiga and G{\"o}ran Ahlgren and Benzaghou Fawzi and Gaillac Bertrand and Billy Amzal and Frans Debruyne and Ga{\"e}lle Fromont and Christian Gratzke and Mark Emberton",

year = "2017",

doi = "10.1016/s1470-2045(16)30661-1",

language = "English",

volume = "18",

pages = "181--191",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "2",

}

Abdel-Rahmène, A, Azzouzi, A, Vincendeau, S, Barret, E, Cicco, A, Kleinclauss, F, van der Poel, H, Stief, C, Rassweiler, J, Salomon, G, Solsona, E, Alcaraz, A, Tammela, T, Rosario, D, Gomez-Veiga, F, Ahlgren, G, Fawzi, B, Bertrand, G, Amzal, B, Debruyne, F, Fromont, G, Gratzke, C & Emberton, M 2017, 'Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial', The Lancet Oncology, Vuosikerta 18, Nro 2, Sivut 181-191. https://doi.org/10.1016/s1470-2045(16)30661-1

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial. / Abdel-Rahmène, Azzouzi; Azzouzi, A; Vincendeau, Sébastien et al.
julkaisussa: The Lancet Oncology, Vuosikerta 18, Nro 2, 2017, s. 181-191.

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : an open-label, phase 3, randomised controlled trial

AU - Abdel-Rahmène, Azzouzi

AU - Azzouzi, A

AU - Vincendeau, Sébastien

AU - Barret, Eric

AU - Cicco, Antony

AU - Kleinclauss, Francois

AU - van der Poel, Henk

AU - Stief, Christian

AU - Rassweiler, Jens

AU - Salomon, Georg

AU - Solsona, Eduardo

AU - Alcaraz, Antonio

AU - Tammela, Teuvo

AU - Rosario, Derek

AU - Gomez-Veiga, Francisco

AU - Ahlgren, Göran

AU - Fawzi, Benzaghou

AU - Bertrand, Gaillac

AU - Amzal, Billy

AU - Debruyne, Frans

AU - Fromont, Gaëlle

AU - Gratzke, Christian

AU - Emberton, Mark

PY - 2017

Y1 - 2017

U2 - 10.1016/s1470-2045(16)30661-1

DO - 10.1016/s1470-2045(16)30661-1

M3 - Article

SN - 1470-2045

VL - 18

SP - 181

EP - 191

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -